Dear Editor-in-Chief
====================

In China, about 112 million people are chronically infected with the hepatitis B virus (HBV) ([@B1]). HBV infection remains a common public health problem worldwide. Study showed that effective antiviral treatment could slow the progression of hepatitis B ([@B2], [@B3]). However, 60% of Chinese chronic hepatitis B patients who were candidates for antiviral treatment were not receiving antiviral treatment ([@B4]). Our previous study indicated that patients receiving antiviral treatment bore heavy economic burden. Health insurance can share economic risks. But beneficiaries of health insurance with low co-payments are likely to use more healthcare resources compared to those paying higher co-payments ([@B5]). So the reasonable co-payments for hepatitis B patients and their willing to pay were of great interest.

Between August and December 2012, we conducted the survey of patients with HBV-related diseases in 3 county hospitals from 3 model regions in Jiangsu Province, China. 430 patients were observed and their attitude toward co-payment was investigated. Among the patients 321 (74.7%) were males and 109 (25.3%) were females. 367 (85.3%) were receiving antiviral treatment, and 63 (14.7%) were not receiving antiviral treatment. In the study, among the five options, nearly 40% patients chose to co-pay 10%--19%. About 80% patients chose co-payment lower than 40%, only 6% patients chose co-payment higher than 60%.Choice of the patient with different economic condition was statistically significant (P\<0.05). There was no significant difference among variable in terms of sex, marital status, insurance type, receiving anti-viral treatment or not.

The results have some implication for public health policy-making. Strengthen health education to highlight the importance of antiviral treatment to effectively control spread of the virus.

###### 

Patients' choice about willing to pay for antiviral treatment

  **Choice Item**   **Number**   **Percentage (%)**   **Cumulative Percentage (%)**
  ----------------- ------------ -------------------- -------------------------------
  \<10%             72           16.7                 16.7
  10%-              97           22.6                 39.3
  20%-              171          39.8                 79.1
  40%-              64           14.9                 94.0
  \>=60%            26           6.0                  100.0
  total             430          100.0                

First-line therapy drugs should be included in the National Essential Medicine List and Medical Insurance Drug list to reimburse part of the medical expenses. Lower than 40% co-payment is acceptable to most patients and adjustments can be made according to economic level.
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